Use of ciprofloxacin in biliary sepsis

Ciprofloxacin is a new carboxylic acid derivative. It is active against gram-positive and gram-negative bacteria, with minimal inhibitory concentrations (MICs) generally around 0.01 mg/l. These favorable properties prompted the authors to study the efficacy and safety of ciprofloxacin in biliary sep...

Full description

Saved in:
Bibliographic Details
Published in:Infection 1988-07, Vol.16 (4), p.249-249
Main Authors: CHRYSANTHOPOULOS, C. J, SKOUTELIS, A. T, STARAKIS, J. C, ARVANITI, A, BASSARIS, H. P
Format: Article
Language:English
Subjects:
Adult
Aged
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - drug therapy
Biliary Tract Diseases - drug therapy
Biological and medical sciences
Ciprofloxacin - therapeutic use
Female
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c342t-b6372c93a44fe669dee94417a691da5dfc84b6d9cd188c44011dacb38882a29a3
cites
container_end_page 249
container_issue 4
container_start_page 249
container_title Infection
container_volume 16
creator CHRYSANTHOPOULOS, C. J
SKOUTELIS, A. T
STARAKIS, J. C
ARVANITI, A
BASSARIS, H. P
description Ciprofloxacin is a new carboxylic acid derivative. It is active against gram-positive and gram-negative bacteria, with minimal inhibitory concentrations (MICs) generally around 0.01 mg/l. These favorable properties prompted the authors to study the efficacy and safety of ciprofloxacin in biliary sepsis. Therapy was successful in 25 patients (including 18 with bacteremia), and failed in five patients.
doi_str_mv 10.1007/BF01650766
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78502538</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78502538</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-b6372c93a44fe669dee94417a691da5dfc84b6d9cd188c44011dacb38882a29a3</originalsourceid><addsrcrecordid>eNqFkM1Lw0AQxRdRaq1evAs5SA9CdGZ3sx9HW6wKBS_2HDabXVhJm5ppQf97Iw31KAwMzPvxmPcYu0a4RwD9MFsAqgK0UidsjFLYHKwWp2wMAiA3yNU5uyD6AIDCSj1iI4GGg8Uxm64oZG3MfNp2bWzaL-fTJuunSk1y3XdGYUuJLtlZdA2Fq2FP2Grx9D5_yZdvz6_zx2XuheS7vFJCc2-FkzIGpWwdgpUStVMWa1fU0RtZqdr6Go3xUgL2Z18JYwx33DoxYdODb__N5z7Qrlwn8qFp3Ca0eyq1KYAXwvwLYgFCgcIevDuAvmuJuhDLbZfWfbISofxtr_xrr4dvBtd9tQ71ER3q6vXbQXfkXRM7t_GJjphGboQE8QMBOHQd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15036061</pqid></control><display><type>article</type><title>Use of ciprofloxacin in biliary sepsis</title><source>Springer Nature - Connect here FIRST to enable access</source><creator>CHRYSANTHOPOULOS, C. J ; SKOUTELIS, A. T ; STARAKIS, J. C ; ARVANITI, A ; BASSARIS, H. P</creator><creatorcontrib>CHRYSANTHOPOULOS, C. J ; SKOUTELIS, A. T ; STARAKIS, J. C ; ARVANITI, A ; BASSARIS, H. P</creatorcontrib><description>Ciprofloxacin is a new carboxylic acid derivative. It is active against gram-positive and gram-negative bacteria, with minimal inhibitory concentrations (MICs) generally around 0.01 mg/l. These favorable properties prompted the authors to study the efficacy and safety of ciprofloxacin in biliary sepsis. Therapy was successful in 25 patients (including 18 with bacteremia), and failed in five patients.</description><identifier>ISSN: 0300-8126</identifier><identifier>EISSN: 1439-0973</identifier><identifier>DOI: 10.1007/BF01650766</identifier><identifier>PMID: 3182091</identifier><identifier>CODEN: IFTNAL</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Aged ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial Infections - drug therapy ; Biliary Tract Diseases - drug therapy ; Biological and medical sciences ; Ciprofloxacin - therapeutic use ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments</subject><ispartof>Infection, 1988-07, Vol.16 (4), p.249-249</ispartof><rights>1989 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-b6372c93a44fe669dee94417a691da5dfc84b6d9cd188c44011dacb38882a29a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=7128340$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3182091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHRYSANTHOPOULOS, C. J</creatorcontrib><creatorcontrib>SKOUTELIS, A. T</creatorcontrib><creatorcontrib>STARAKIS, J. C</creatorcontrib><creatorcontrib>ARVANITI, A</creatorcontrib><creatorcontrib>BASSARIS, H. P</creatorcontrib><title>Use of ciprofloxacin in biliary sepsis</title><title>Infection</title><addtitle>Infection</addtitle><description>Ciprofloxacin is a new carboxylic acid derivative. It is active against gram-positive and gram-negative bacteria, with minimal inhibitory concentrations (MICs) generally around 0.01 mg/l. These favorable properties prompted the authors to study the efficacy and safety of ciprofloxacin in biliary sepsis. Therapy was successful in 25 patients (including 18 with bacteremia), and failed in five patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial Infections - drug therapy</subject><subject>Biliary Tract Diseases - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><issn>0300-8126</issn><issn>1439-0973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><recordid>eNqFkM1Lw0AQxRdRaq1evAs5SA9CdGZ3sx9HW6wKBS_2HDabXVhJm5ppQf97Iw31KAwMzPvxmPcYu0a4RwD9MFsAqgK0UidsjFLYHKwWp2wMAiA3yNU5uyD6AIDCSj1iI4GGg8Uxm64oZG3MfNp2bWzaL-fTJuunSk1y3XdGYUuJLtlZdA2Fq2FP2Grx9D5_yZdvz6_zx2XuheS7vFJCc2-FkzIGpWwdgpUStVMWa1fU0RtZqdr6Go3xUgL2Z18JYwx33DoxYdODb__N5z7Qrlwn8qFp3Ca0eyq1KYAXwvwLYgFCgcIevDuAvmuJuhDLbZfWfbISofxtr_xrr4dvBtd9tQ71ER3q6vXbQXfkXRM7t_GJjphGboQE8QMBOHQd</recordid><startdate>19880701</startdate><enddate>19880701</enddate><creator>CHRYSANTHOPOULOS, C. J</creator><creator>SKOUTELIS, A. T</creator><creator>STARAKIS, J. C</creator><creator>ARVANITI, A</creator><creator>BASSARIS, H. P</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19880701</creationdate><title>Use of ciprofloxacin in biliary sepsis</title><author>CHRYSANTHOPOULOS, C. J ; SKOUTELIS, A. T ; STARAKIS, J. C ; ARVANITI, A ; BASSARIS, H. P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-b6372c93a44fe669dee94417a691da5dfc84b6d9cd188c44011dacb38882a29a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial Infections - drug therapy</topic><topic>Biliary Tract Diseases - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHRYSANTHOPOULOS, C. J</creatorcontrib><creatorcontrib>SKOUTELIS, A. T</creatorcontrib><creatorcontrib>STARAKIS, J. C</creatorcontrib><creatorcontrib>ARVANITI, A</creatorcontrib><creatorcontrib>BASSARIS, H. P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHRYSANTHOPOULOS, C. J</au><au>SKOUTELIS, A. T</au><au>STARAKIS, J. C</au><au>ARVANITI, A</au><au>BASSARIS, H. P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of ciprofloxacin in biliary sepsis</atitle><jtitle>Infection</jtitle><addtitle>Infection</addtitle><date>1988-07-01</date><risdate>1988</risdate><volume>16</volume><issue>4</issue><spage>249</spage><epage>249</epage><pages>249-249</pages><issn>0300-8126</issn><eissn>1439-0973</eissn><coden>IFTNAL</coden><abstract>Ciprofloxacin is a new carboxylic acid derivative. It is active against gram-positive and gram-negative bacteria, with minimal inhibitory concentrations (MICs) generally around 0.01 mg/l. These favorable properties prompted the authors to study the efficacy and safety of ciprofloxacin in biliary sepsis. Therapy was successful in 25 patients (including 18 with bacteremia), and failed in five patients.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>3182091</pmid><doi>10.1007/BF01650766</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-8126
ispartof Infection, 1988-07, Vol.16 (4), p.249-249
issn 0300-8126
1439-0973
language eng
recordid cdi_proquest_miscellaneous_78502538
source Springer Nature - Connect here FIRST to enable access
subjects Adult
Aged
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - drug therapy
Biliary Tract Diseases - drug therapy
Biological and medical sciences
Ciprofloxacin - therapeutic use
Female
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
title Use of ciprofloxacin in biliary sepsis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T20%3A36%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20ciprofloxacin%20in%20biliary%20sepsis&rft.jtitle=Infection&rft.au=CHRYSANTHOPOULOS,%20C.%20J&rft.date=1988-07-01&rft.volume=16&rft.issue=4&rft.spage=249&rft.epage=249&rft.pages=249-249&rft.issn=0300-8126&rft.eissn=1439-0973&rft.coden=IFTNAL&rft_id=info:doi/10.1007/BF01650766&rft_dat=%3Cproquest_cross%3E78502538%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c342t-b6372c93a44fe669dee94417a691da5dfc84b6d9cd188c44011dacb38882a29a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15036061&rft_id=info:pmid/3182091&rfr_iscdi=true